AXNX:NSD-Axonics Modulation Technologies Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 68.72

Change

-0.18 (-0.26)%

Market Cap

USD 3.52B

Volume

0.49M

Analyst Target

USD 52.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. Address: 26 Technology Drive, Irvine, CA, United States, 92618

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.52 (+0.75%)

USD 27.85B
PODD Insulet Corporation

+0.57 (+0.24%)

USD 16.40B
BRKR Bruker Corporation

+1.77 (+2.72%)

USD 9.94B
MASI Masimo Corporation

-0.70 (-0.61%)

USD 6.03B
TMDX TransMedics Group Inc

-0.12 (-0.08%)

USD 5.04B
PRCT Procept Biorobotics Corp

+3.16 (+3.96%)

USD 4.00B
QDEL Quidel Corporation

-0.12 (-0.26%)

USD 3.06B
TNDM Tandem Diabetes Care Inc

-0.42 (-0.98%)

USD 2.88B
LIVN LivaNova PLC

+0.07 (+0.14%)

USD 2.64B
NARI Inari Medical Inc

+0.28 (+0.63%)

USD 2.61B

ETFs Containing AXNX

MARB First Trust Vivaldi Merge.. 4.05 % 0.00 %

-0.01 (0.00%)

USD 0.03B
EVNT AltShares Event-Driven ET.. 2.98 % 0.00 %

N/A

USD 4.78M
ARB AltShares Trust - AltShar.. 0.00 % 0.00 %

-0.01 (0.00%)

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.43% 76% C+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.43% 76% C+ 67% D+
Trailing 12 Months  
Capital Gain 16.97% 75% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.97% 75% C 64% D
Trailing 5 Years  
Capital Gain 120.47% 95% A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.47% 95% A 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 25.27% 77% C+ 81% B-
Dividend Return 25.27% 77% C+ 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.34% 71% C- 45% F
Risk Adjusted Return 62.63% 96% N/A 85% B
Market Capitalization 3.52B 94% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.